Weiyuan County Deyuantang Pharmaceutical Co., Ltd..

Founded in November 2014, the company has registered capital of 10.68 million yuan, covering an area of 15 mu, with 132 employees, including 37 managers. The company mainly produces, processes and sells Chinese herbal medicines, cultivates, stores and sells authentic Chinese herbal medicines, develops Chinese herbal medicines and provides information consulting services as its main business. It is a modern Chinese herbal medicine enterprise with refined Chinese herbal medicines as its main industry.
Obtaining Pharmaceutical Production License in November 2014
In February 2015, the company obtained the national GMP certificate. At present, the main products listed by the company are Angelica sinensis, Codonopsis pilosula, Astragalus membranaceus, Licorice, Bupleurum, Dandelion, Epimedium, etc.
In June 2015, our company set up the E-Commerce Department, cooperating with Taobao Mall, Shanrong Mall and Alibaba Mall. Through the online business model, the turnover in 2015 exceeded 1 million yuan, in 2016 exceeded 5 million yuan and in 2017 exceeded 8 million yuan.
In 2016, three new patents were obtained: a multi-purpose Angelica planting structure, a modern Angelica planting structure and a self-sowing Angelica planting structure.
In March 2016, we obtained the import and export license. Our products are exported to Korea, Japan and other countries in Southeast Asia. The market prospects are very broad.
In 2017, Niu Jiabao trademark was registered successfully. In August, he obtained the certificate of high-tech enterprises in Gansu Province. The company adopts the business model of "company + base + cooperative + peasant household", unified planning, unified guidance, unified acquisition, and has built 4000 mu herbal medicine planting base.
At present, the output value of production is 70 million yuan, the sales volume is more than 46 million yuan, and the tax payment is more than 400,000 yuan. It is expected that the annual low will break through the 100 million mark.